As a service to the global R&D community, Science|Business has compiled this database of funding opportunities. Users are encouraged to let us know of funding calls that could be incorporated into the database. Please email all suggestions to [email protected]. The database will be updated daily. For rapid news about COVID-19, see our live blog.
Project should focus on multi-site clinical trials to address ageing-related issues such as reducing transmission, risk, morbidity, mortality, severity, or complications of COVID-19.
Amount
Not limited
Agency or Funder
National Institutes of Health and National Institute on Aging
Eligibility (if available)
Higher education institutions, nonprofits, for-profit organisations, local and federal governments, non-U.S entities, non-U.S. components of U.S. organisations
Competitive revisions to active grants in projects focusing on viral natural history, pathogenicity, transmission, as well as projects developing medical countermeasures and suitable animal models for pre-clinical testing of vaccines and therapeut
Amount
Not limited
Agency or Funder
U.S. National Institutes of Health (NIH) - NIAID & NIGMS
Eligibility (if available)
Existing grantholders wishing to expand the scope of their research.
Competitive revisions to active grants in projects focusing on viral natural history, pathogenicity, transmission, as well as projects developing medical countermeasures and suitable animal models for pre-clinical testing of vaccines and therapeut
Agency or Funder
National Institute of Allergy and Infectious Diseases (NIAID)
UKRI calls for projects with potential to deliver a significant contribution to the understanding, prevention or management of the COVID-19 outbreak within 12 months.
Amount
UK - 80% of full economic costs. Overseas - 100% direct costs only
Agency or Funder
UK Research and Innovation and the Department of Health and Social Care
Eligibility (if available)
Principal investigator must be hosted by an institution eligible for UKRI funding.
NIAID announces that a number of existing calls will particularly welcome research objectives related to pathogenicity, transmission, medical countermeasures, pre-clinical testing of vaccines and therapeutics.
Agency or Funder
National Institute of Allergy and Infectious Diseases (NIAID)